Cirrus Therapeutics

About Cirrus Therapeutics

Cirrus Therapeutics is a biotechnology company focused on ocular immunology, developing transformative therapies to treat age-related macular degeneration (AMD). Their mission is to preserve sight, extend ocular healthspan, and redefine healthy aging for vision by creating preventative and restorative treatments that address the root causes of vision loss.

Products & Services

Dry AMD Therapy:A breakthrough gene therapy using an adeno-associated viral (AAV) vector to restore IRAK-M protein levels in the eye, aiming to rejuvenate the eye's natural defenses, reduce inflammation, protect retinal cells, and potentially halt or reverse early vision loss caused by dry age-related macular degeneration (AMD).

Specialties

Ocular Immunology Gene Therapy Age-Related Macular Degeneration (AMD) Treatment Retinal Health

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Seed T: - FT: Seed	A: 11000000 MR: - FA: $11 million FAN: 11000000	D: 2025-10-02 FD: 2025-10-02	3 investors

Seed Latest

2025-10-02

$11.0M

3 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

Y

Ying Kai Chan

Chief Executive Officer and Co-Founder

LinkedIn (Pro only)

A

Andrew Dick

Chief Scientific Advisor and Co-Founder

LinkedIn (Pro only)

A

Alexandra Cantley

Partner, Polaris Partners

LinkedIn (Pro only)

K

Khoo Shih

CEO, ClavystBio

J

James Handa

Robert Bond Welch Professor and Chief of the Retina Division

F

Frank Holz

Chairman and Professor, Department of Ophthalmology, The University of Bonn

View 8 more team members with Pro

Unlock Full Team Directory

Recent News